BioCentury | Sep 30, 2013
Company News

Egis Pharmaceuticals, Servier deal

...account for 75% of sales revenues. Servier reported 2012 sales of €3.9 billion ($5.1 billion). Egis Pharmaceuticals plc...
BioCentury | Jun 11, 2007
Company News

Apotex, Egis Pharmaceuticals, Eli Lilly, Teva Pharmaceuticals Industry Ltd. neurology news

...Jan. 1). Zyprexa had 2006 global sales of $4.4 billion. Apotex Inc. , Weston, Ontario Egis Pharmaceuticals plc...
BioCentury | Feb 24, 2003
Clinical News

Deramciclane: Phase III

...PHA to develop the compound partly compensated for the cost of the Phase III trials. Egis Pharmaceuticals...
BioCentury | Feb 18, 2003
Clinical News

Orion discontinues deramciclane for GAD

...consider developing the compound for other indications. Orion licensed deramciclane, a selective 5-HT2 antagonist, from Egis Pharmaceuticals...
BioCentury | Sep 4, 2001
Company News

Orion, Pharmacia deal

...U.S. and will receive a $30 million upfront payment and milestones. Orion licensed deramciclane from Egis Pharmaceuticals...
BioCentury | Aug 27, 2001
Company News

Orion, Pharmacia anxiety deal

...will receive a $30 million upfront payment and milestones. Orion originally licensed deramciclane from Hungary-based Egis Pharmaceuticals. BC...
Items per page:
1 - 6 of 6
BioCentury | Sep 30, 2013
Company News

Egis Pharmaceuticals, Servier deal

...account for 75% of sales revenues. Servier reported 2012 sales of €3.9 billion ($5.1 billion). Egis Pharmaceuticals plc...
BioCentury | Jun 11, 2007
Company News

Apotex, Egis Pharmaceuticals, Eli Lilly, Teva Pharmaceuticals Industry Ltd. neurology news

...Jan. 1). Zyprexa had 2006 global sales of $4.4 billion. Apotex Inc. , Weston, Ontario Egis Pharmaceuticals plc...
BioCentury | Feb 24, 2003
Clinical News

Deramciclane: Phase III

...PHA to develop the compound partly compensated for the cost of the Phase III trials. Egis Pharmaceuticals...
BioCentury | Feb 18, 2003
Clinical News

Orion discontinues deramciclane for GAD

...consider developing the compound for other indications. Orion licensed deramciclane, a selective 5-HT2 antagonist, from Egis Pharmaceuticals...
BioCentury | Sep 4, 2001
Company News

Orion, Pharmacia deal

...U.S. and will receive a $30 million upfront payment and milestones. Orion licensed deramciclane from Egis Pharmaceuticals...
BioCentury | Aug 27, 2001
Company News

Orion, Pharmacia anxiety deal

...will receive a $30 million upfront payment and milestones. Orion originally licensed deramciclane from Hungary-based Egis Pharmaceuticals. BC...
Items per page:
1 - 6 of 6